Amelanotic Melanoma Tied to Worse Survival
TOPLINE:
Patients with amelanotic melanoma showed poorer disease-specific survival (DSS) than those with melanotic melanoma in a Surveillance, Epidemiology, and End Results (SEER) database analysis.
METHODOLOGY:
Researchers analyzed data on patients with invasive cutaneous amelanotic melanoma (n = 1598) and melanotic melanoma (n = 417,974) from the SEER 17 database between 2000 and 2021.
Patients with amelanotic melanoma were older at diagnosis and presented with more advanced-stage disease than those with melanotic melanoma (regional/distant stages: 26.8% vs 12.4%), ulceration (35.6% vs 13.1%), and Breslow thickness > 2 mm (42% vs 17%).
The primary outcome was DSS.
TAKEAWAY:
Five-year DSS was significantly lower in patients with amelanotic melanoma (78.6%) than in those with melanotic melanoma (91.3%; P < .001).
Patients with amelanotic melanoma carried a 31% higher risk for mortality after adjusting for sex, age, and stage (P < .001).
Among those with amelanotic melanoma, men (hazard ratio [HR], 1.38; P = .014 vs women) had a higher disease-specific mortality, and mortality was higher among adults aged 85 years and older (HR, 1.86; P = .002 vs patients aged 45-64 years).
Amelanotic melanoma diagnoses made 2011 onward were associated with a lower mortality risk (HR, 0.55; P < .001) than those diagnosed before 2011, with 2-year DSS for distant metastases more than doubling from 26.4% during 2000-2005 to 58.8% during 2016-2021.
IN PRACTICE:
'This study underscores the poorer survival outcomes associated with AM [amelanotic melanoma] compared to MM [melanotic melanoma] and highlights a potential survival improvement following the availability of immunotherapy,' the study authors wrote. They called for prospective trials 'to validate these findings and guide tailored management strategies for AM.'
SOURCE:
The study was led by Trang M. Nguyen, MD, National Hospital of Dermatology and Venereology, Hanoi, Vietnam, and was published online on June 12 in Journal of the American Academy of Dermatology.
LIMITATIONS:
Limitations included selection bias and limited follow-up for recent cases.
DISCLOSURES:
The authors reported having no funding sources or relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Federal Proposals Threaten Provider Taxes
Republican efforts to restrict taxes on hospitals, health plans, and other providers that states use to help fund their Medicaid programs could strip them of tens of billions of dollars. The move could shrink access to healthcare for some of the nation's poorest and most vulnerable people, warn analysts, patient advocates, and democratic political leaders. No state has more to lose than California, whose Medicaid program, called Medi-Cal, covers nearly 15 million residents with low incomes and disabilities. That's twice as many as New York and three times as many as Texas. A proposed rule by the Centers for Medicare & Medicaid Services, echoed in the Republican House reconciliation bill as well as a more drastic Senate bill, would significantly curtail the federal dollars many states draw in matching funds from what are known as provider taxes. Although it's unclear how much states could lose, the revenue up for grabs is big. For instance, California has netted an estimated $8.8 billion this fiscal year from its tax on managed care plans and took in about $5.9 billion last year from hospitals. California Democrats are already facing a $12 billion deficit, and they have drawn political fire for scaling back some key healthcare policies, including full Medi-Cal coverage for immigrants without permanent legal status. And a loss of provider tax revenue could add billions to the current deficit, forcing state lawmakers to make even more unpopular cuts to Medi-Cal benefits. 'If Republicans move this extreme MAGA proposal forward, millions will lose coverage, hospitals will close, and safety nets could collapse under the weight,' Gov. Gavin Newsom, a Democrat, said in a statement, referring to President Donald Trump's 'Make America Great Again' movement. The proposals are also a threat to Proposition 35, a ballot initiative California voters approved last November to make permanent the tax on managed care organizations, or MCOs, and dedicate some of its proceeds to raise the pay of doctors and other providers who treat Medi-Cal patients. All states except Alaska have at least one provider tax on managed care plans, hospitals, nursing homes, emergency ground transportation, or other types of healthcare businesses. The federal government spends billions of dollars a year matching these taxes, which generally lead to more money for providers, helping them balance lower Medicaid reimbursement rates while allowing states to protect against economic downturns and budget constraints. New York, Massachusetts, and Michigan would also be among the states hit hard by Republicans' drive to scale back provider taxes, which allow states to boost their share of Medicaid spending to receive increased federal Medicaid funds. In a May 12 statement announcing its proposed rule, CMS described a 'loophole' as 'money laundering,' and said California had financed coverage for over 1.6 million 'illegal immigrants' with the proceeds from its MCO tax. CMS said its proposal would save more than $30 billion over 5 years. 'This proposed rule stops the shell game and ensures federal Medicaid dollars go where they're needed most — to pay for healthcare for vulnerable Americans who rely on this program, not to plug state budget holes or bankroll benefits for noncitizens,' Mehmet Oz, the CMS administrator, said in the statement. Medicaid allows coverage for noncitizens who are legally present and have been in the country for at least 5 years. And California uses state money to pay for almost all of the Medi-Cal coverage for immigrants who are not in the country legally. California, New York, Michigan, and Massachusetts together account for more than 95% of the 'federal taxpayer losses' from the loophole in provider taxes, CMS said. But nearly every state would feel some impact, especially under the provisions in the reconciliation bill, which are more restrictive than the CMS proposal. None of it is a done deal. The CMS proposal, published May 15, has not been adopted yet, while the House and Senate bills must be negotiated into one and passed by both chambers of Congress. But the restrictions being contemplated would be far-reaching. A report by Michigan's Department of Health and Human Services, ordered by Democratic Gov. Gretchen Whitmer, found that a reduction of revenue from the state's hospital tax could 'destabilize hospital finances, particularly in rural and safety-net facilities, and increase the risk of service cuts or closures.' Losing revenue from the state's MCO tax 'would likely require substantial cuts, tax increases, or reductions in coverage and access to care,' it said. CMS declined to respond to questions about its proposed rule. The Republicans' House-passed reconciliation bill, though not the CMS proposal, also prohibits any new provider taxes or increases to existing ones. The Senate version, released on June 16, would gradually reduce the allowable amount of many provider taxes. The American Hospital Association, which represents nearly 5000 hospitals and health systems nationwide, said the proposed moratorium on new or increased provider taxes could force states 'to make significant cuts to Medicaid to balance their budgets, including reducing eligibility, eliminating or limiting benefits, and reducing already low payment rates for providers.' Because provider taxes draw matching federal dollars, Washington has a say in how they are implemented. And the Republicans who run the federal government are looking to spend far fewer of those dollars. In California, the insurers that pay the MCO tax are reimbursed for the portion levied on their Medi-Cal enrollment. That helps explain why the tax rate on Medi-Cal enrollment is sharply higher than on commercial enrollment. Over 99% of the tax money the insurers pay comes from their Medi-Cal business, which means most of the state's insurers get back almost all the tax they pay. That imbalance, which CMS describes as a loophole, is one of the main things Republicans are trying to change. If either the CMS rule or the corresponding provisions in the House reconciliation bill were enacted, states would be required to levy provider taxes equally on Medicaid and commercial business to draw federal dollars. California would likely be unable to raise the commercial rates to the level of the Medi-Cal ones because state law constrains the legislature's ability to do so. The only way to comply with the rule would be to lower the tax rate on Medi-Cal enrollment, which would sharply reduce revenue. CMS has warned California and other states for years, including under the Biden administration, that it was considering significant changes to MCO and other provider taxes. Those warnings were never realized. But the risk may be greater this time, some observers say, because the effort to shrink provider taxes is embedded in both Republican reconciliation bills and intertwined with a broader Republican strategy — and set of proposals — to cut Medicaid spending by $800 billion or more. 'All of these proposals move in the same direction: Fewer people enrolled, less generous Medicaid programs over time,' said Edwin Park, a research professor at Georgetown University's McCourt School of Public Policy. California's MCO tax is expected to net California $13.9 billion over the next two fiscal years, according to January estimates. The state's hospital tax is expected to bring in an estimated $9 billion this year, up sharply from last year, according to the Department of Health Care Services, which runs Medi-Cal. Losing a significant slice of that revenue on top of other Medicaid cuts in the House reconciliation bill 'all adds up to be potentially a super serious impact on Medi-Cal and the California state budget overall,' said Kayla Kitson, a senior policy fellow at the California Budget & Policy Center. And it's not only California that will feel the pain. 'All states are going to be hurt by this,' Park said.
CNN
an hour ago
- CNN
How Far Are We from Animal Organs Saving Lives? - Chasing Life with Dr. Sanjay Gupta - Podcast on CNN Audio
Dr. Sanjay Gupta 00:00:03 'Welcome to Paging Dr. Gupta. This is one of my favorite parts of the week, because I get a chance to connect with you, to answer your questions, and to hear what's on your mind. I also often get to talk about some of the big medical developments that are shaping our lives. If you caught last week's episode, for example, you know that we've been diving into something that sounds very much like science fiction, but at the same time has become very real, quickly, xeno-transplantation, X-E-N-O, transplantation. That is the medical term for transplanting organs from one species into another. In this case, specifically from animals into humans. Even more specifically, from pigs into people. Now, I'm so fascinated by this. I spent two years working on a documentary and we covered everything from the special pig farms to operating rooms. Scientists, surgeons, and patients who are making this happen. I spent a lot of time with all of them. Today, I'm really excited to keep the conversation going by answering the many questions you guys sent in. So let's get into it. Kyra's back with us. What do we have, Kyra? What's up first? Kyra Dahring 00:01:20 Yeah, so Paul wrote in wondering something pretty fascinating about personalized organs, and I'm gonna read it to you. So he wrote: over the past two decades, work was happening in the area of using one's cell makeup to create an organ in the lab. Is this still an approach being considered? Dr. Sanjay Gupta 00:01:37 Okay, Paul, this is a great question. And the answer is yes. There is work that is being done in this particular space of creating basically individualized organs. One of the efforts of a company known as United Therapeutics, they work in the xenotransplant area, one of their efforts is also in creating what can best be called ghost organs. And we got a chance to see this. So imagine this, okay, so you have a pig organ, maybe a pig heart in this case, and it essentially is cleansed using these detergents of all of its biology, of all its cells. The only thing left is the scaffolding of the organ, okay? And then that scaffolding is essentially repopulated, reseeded with human cells, a specific human cells. Now, if you think about that, that essentially now is a personalized organ for somebody. This approach, this idea of creating ghost organs, is still further off than where we are currently with xenotransplantation. But I think to your question, this is the future. These ghost organs that are repopulated with an individual's human cells to create a personalized organ, that may be what we can expect in the future, so for example, let's say you have cardiac disease or you have some sort of disease where you know you're gonna need a transplant in the feature. You could potentially create a personalized organ that would be ready to go when you need it. Before your condition gets too far along, scientists could take some of your cells, simply from your blood or your skin, grow those cells, and then use them to populate the ghost organ scaffolding. Not only do you have an organ designed for you, but because they are your cells immunosuppression, rejection, acceptance, that shouldn't be an issue. It is essentially your organ. Now stick around, after the break we're going to get into just how many of these pig kidneys have actually made it into humans, and the bigger question, could this really solve the organ shortage crisis? Dr. Sanjay Gupta 00:03:54 Okay, we're gonna try and get to as many pages as possible. Kyra, what do we have next? Kyra Dahring 00:03:59 'Next is Ann from Kansas, and she wants to know, you know, how many pig kidney transplants have been done? Whether anyone's lived long-term with them? And if they use different anti-rejection meds than the typical transplant. Dr. Sanjay Gupta 00:04:14 'All right, first of all, how many kidney xenotransplants? Four in two living patients. And the reason I say living patients is because the first couple of transplants were actually done into patients who were brain dead. These were patients who had signed up to be organ donors, but instead in a way they became organ recipients when they were brain-dead. It was an opportunity for scientists to try and study, could these pig organs actually survive in the human body and they found that it worked. So in March of 2024, the first patient, a guy named Rick Slayman at Massachusetts General Hospital got a transplant, a xenotransplant, and he lived for two additional months. In April 2024, a month later, Lisa Pisano got a transplant, lived for a two additional month. A few months later, November of 2024 the third patient, Towana Looney at NYU got a pig kidney. She is still alive, but had to have the pig kidney removed after 130 days because of an unrelated infection. And then in January of 2025, this year, Tim Andrews, the fourth patient, he still has his xenotransplant and soon is gonna surpass 130 days, becoming the longest survivor in the world with a xenotransplant. Now, in addition to the four xeno kidney transplants, there have been two pig heart transplants as well, both at the University of Maryland School of Medicine. January of 2022, David Bennett lived for two additional months. September of 2023, Larry Faucette lived for an additional six weeks. Now, I just wanted to name everybody there because all the folks I just mentioned are pioneers. They volunteered, they put their hands up to do something that had never been done before. And they really sort of ventured out into the unknown. Very, very brave. And as a result of their efforts, they have really advanced science. That's why I wanted to give you all their names. Now, with regard to the second part of your question, the immunosuppression or the anti-rejection medications are very similar to what a human-to-human transplant would take, but typically at higher doses. So similar meds, but higher doses of the meds. And typically a few other drugs that have been added into the regimen, which have been shown to be effective so far in these early studies. The key to the success though, make no mistake, is the engineering of the pig's DNA to make it more similar to a human's. In some cases, there were some genes that were removed. In other cases, certain trans genes were added. So human genes actually added into pig's genome. All right, Kyra, what's our last question? Kyra Dahring 00:07:08 All right, Sanjay, we're wrapping up with one from Alia in Kuwait. She's asking a pretty big picture question: how far are we from this being a solution to the organ crisis? Dr. Sanjay Gupta 00:07:19 Well, Alia, first of all, thanks for calling us from Kuwait. Five years. Five years is the number that I was given over and over again. Kidneys, in part, are going to be the first organs to really get to scale, but it sounds like they're also going to get to hearts, livers, and possibly lungs. We're about to enter clinical trials this summer with United Therapeutics, and we had a chance to visit the farm where they're raising the pigs for the trials. These are biosecure farms, look nothing like a typical farm. They have these filters and clean water and air. In some ways the food and the water and the air that the pigs are getting is even cleaner than what the humans are getting that work there. They have a high level of security. They have their operating rooms right there on campus. So they take the organs there and then send the organs directly to recipients around the country. I don't know, Alia, that I would necessarily say that this is going to solve the organ shortage crisis, but I think it's going to be a very important stopgap. Keep in mind, some of these farms can raise thousands of pigs, and there's a few of these farms around the country, but there's 100,000 people on the waiting list for organs in the United States alone. 17 people who die waiting for an organ. So we're going to need hundreds of thousands of organs potentially to try and solve the organ shortage crisis. And then there are a lot of people who don't currently qualify for transplant, even though they probably should, they're just not sick enough. Then the question becomes, could these pig organs start to supply organs to those folks as well? It's a fascinating field. It combines so many different scientific developments. IVF, cloning, CRISPR gene editing, transplant immunology, transplant surgery. All these scientific developments, some of them Nobel Prize winning developments, came together to create this field of xenotransplantation and potentially save and extend a lot of lives in the process. Dr. Sanjay Gupta 00:09:28 'Thanks for being so fascinated by this like I am and thank you for writing in your questions, sending in your question. I always love hearing what you're curious about. And if there's something else health related you've been wondering about, don't be shy, record a voice memo, email it to AskSanjay@ or give us a call, 470-396-0832, leave a message, and be sure to check out part two of our Chasing Life special on xenotransplantation. I'm gonna dive even deeper into what this breakthrough could mean for the future of medicine overall. The documentary is called Animal Pharm, P-H-A-R-M, and part two will be on the feed Friday. Thanks for listening, and I'll be back next Tuesday. Chasing Life is a production of CNN Audio. Our podcast is produced by Eryn Mathewson, Jennifer Lai, Grace Walker, Lori Galaretta, Jesse Remedios, Sofia Sanchez, Kyra Dahring, and Madeleine Thompson. Andrea Kane is our medical writer, our senior producer is Dan Bloom, Amanda Sealy is our showrunner, Dan Dzula is our technical director, and the executive producer of CNN Audio is Steve Lickteig. With support from Jamus Andrest, Jon Dianora, Haley Thomas, Alex Manasseri, Robert Mathers, Leni Steinhardt, Nichole Pesaru, and Lisa Namerow. Special thanks to Ben Tinker and Nadia Kounang of CNN Health and Wendy Brundige.
Associated Press
an hour ago
- Associated Press
Antifungal Brand Crystal Flush Explains Why Toe Fungus Is More Common After Retirement (and How to Fight It)
06/23/2025, Los Angeles, CA // PRODIGY: Feature Story // Retirement brings freedom, but can also bring foot problems you didn't expect. With more time spent barefoot around the house, gardening in damp soil, or enjoying group activities like swimming, golf, or gym workouts, your feet are exposed to more moisture and bacteria than ever. And when toes stay damp or come into contact with communal surfaces, the risk of fungal infection increases quickly. Fungus thrives in warm, moist environments, especially when nails are already thick, brittle, or slightly damaged. Many retirees don't realize their casual habits—like walking barefoot at home or skipping proper foot care after a long day outdoors—can quietly lead to stubborn infections. Once the fungus takes hold, it can discolor, thicken, and even break the nails of the toes, making it painful to walk and frustrating to treat. That's why Crystal Flush developed these two incredible products: the Antifungal Serum and Therapeutic Foot Soak. Use the serum daily to deliver maximum-strength protection and kill fungus at the root, thanks to FDA-approved Tolnaftate 1% and seven essential oils. After high-risk activities like gardening or gym sessions, soak your feet in the Foot Soak to draw out bacteria, soothe tired muscles, and restore balance with natural tea tree oil and Epsom salts. Keep enjoying your well-earned retirement, without letting toe fungus tag along. The Crystal Flush Antifungal Serum and Therapeutic Foot Soak are available at Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis or treatment of any condition. Media Contact: Jason Gonor 888-717-5722
